Life Science and Humanity
Advancing health research while preserving human values and ethical frameworks across Africa.
Latest Articles
View More Articles →
Personalised mRNA Cancer Vaccine Achieves Historic Phase 3 Success in Melanoma Trial
The INTerpath-001 Phase 3 trial of intismeran autogene, a personalised mRNA vaccine developed by Moderna and Merck, has met its primary endpoint of recurrence-free survival in over 1,100 patients with high-risk melanoma when combined with pembrolizumab — the first late-stage randomised trial of a personalised cancer vaccine to succeed.
Largest Ebola Outbreak in DRC History Driven by Bundibugyo Virus Prompts Global Vaccine Deployment
The Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo has surpassed 4,665 confirmed cases across six provinces, becoming the largest Ebola outbreak ever recorded in the country and prompting the allocation of 70,000 doses of Ervebo vaccine for clinical trial and frontline worker protection.
Landmark Lancet Study Confirms RTS,S Malaria Vaccine Averts One in Eight Child Deaths Across Pilot Nations
A four-year evaluation of the world's first malaria vaccine pilot published in The Lancet confirms a 13% reduction in all-cause child mortality across Ghana, Kenya, and Malawi — even at moderate coverage levels — strengthening the case for accelerated rollout across 25 African nations.
AIDS 2026: Once-Weekly Oral HIV Treatment and African-Led Vaccine Trials Headline Rio Conference
The 26th International AIDS Conference in Rio de Janeiro showcased Phase 3 results showing a once-weekly oral islatravir/lenacapavir regimen maintains viral suppression, the launch of Africa's first indigenous HIV vaccine trial BRILLIANT 011, and stark warnings about the impact of global funding cuts on HIV services in eastern and southern Africa.
MTBVAC TB Vaccine Candidate Reaches Full Enrollment in Phase 2b IMAGINE Trial Across Three African Nations
On 16 July 2026, the Phase 2b IMAGINE trial of the MTBVAC tuberculosis vaccine candidate completed enrollment of 5,500 participants across 16 centres in South Africa, Kenya, and Tanzania. The milestone advances the search for a new TB vaccine to complement the century-old BCG, as results from the Phase III PreVenTB trial earlier in 2026 showed that two other candidates failed to meet their primary endpoint.
Sudan Declares End to Year-Long Cholera Outbreak After 124,000 Cases and 3,573 Deaths
On 3 March 2026, Sudan's Federal Ministry of Health and WHO declared the end of a cholera outbreak that swept all 18 states since July 2024, infecting over 124,000 people and killing 3,573. Vaccination campaigns protected more than 23 million people, but experts warn that conflict-driven infrastructure collapse leaves the country vulnerable to resurgence.
South Africa Launches BRILLIANT 011: Africa's First-In-Human HIV Vaccine Trial in Cape Town
On 22 January 2026, the South African Medical Research Council launched the BRILLIANT 011 Phase 1 clinical trial at Groote Schuur Hospital in Cape Town — the first-in-human HIV vaccine study designed and led by African scientists, targeting strains circulating in Southern Africa. The trial survived near-cancellation after US funding cuts in early 2025.
WHO Reports Clade Ib Mpox Community Transmission Across Six Regions Despite End of Global Emergency
A WHO Disease Outbreak News report published on 5 December 2025 documented 43 new confirmed clade Ib mpox cases across six WHO regions since the lifting of the global emergency in September, with community transmission now established in Italy, the Netherlands, Portugal, Spain, the United States, and Malaysia.